Compare SFIX & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SFIX | ABEO |
|---|---|---|
| Founded | 2011 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 412.3M | 399.5M |
| IPO Year | 2017 | 2005 |
| Metric | SFIX | ABEO |
|---|---|---|
| Price | $2.21 | $5.44 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $4.50 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 2.4M | 1.3M |
| Earning Date | 06-09-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 59.09 | ★ 165.16 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,226,505,000.00 | $2,998,000.00 |
| Revenue This Year | $8.04 | $1,024.31 |
| Revenue Next Year | $3.73 | $145.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 25.52 | ★ 258.18 |
| 52 Week Low | $2.10 | $4.00 |
| 52 Week High | $5.75 | $7.65 |
| Indicator | SFIX | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 24.48 | N/A |
| Support Level | N/A | N/A |
| Resistance Level | $3.58 | N/A |
| Average True Range (ATR) | 0.13 | 0.00 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 5.85 | 0.00 |
Stitch Fix Inc offers personal style services for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandise with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types, and price points including Women's, Petite, Maternity, Men's, and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry, and handbags and sells merchandise across various ranges of price points.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.